Oncologists Audition Yervoy And Zelboraf For First-line Roles, With New Combos In Near Sight

Cooperative group plans trial testing Yervoy vs. Zelboraf in first-line metastatic melanoma to help settle the issue of which therapy should come first in BRAF-mutation positive patients. New therapies on the way promise to further complicate decision-making.